Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and the Timing of Immune Activation and Restraint: Study Summary

Previous related pageVitamin D and the Timing of Immune Activation and Restraint: Full Evidence ReviewNext related pageVitamin D and the Timing of Immune Activation and Restraint: Full Evidence Review
Study at a glance

What was studied?

Researchers examined human immune cells in the laboratory, including cells from inflamed rheumatoid joints. They measured cell division, inflammatory signals and functions that reduce activation of other cells. Blood-marker reports from one human trial provided a separate comparison.

What was found?

Vitamin D effects differed with time and cell type. One study found greater expansion than in similar cultures not given active hormone at day four but lower division measures than that comparison at day seven. Other experiments found changes in restraining functions. The hormone had less effect on some cells from inflamed joints than on blood-derived cells. Not every inflammatory signal fell.

What does it mean?

Cell expansion, inflammatory signals and tissue recovery are different outcomes. A lower blood marker at one visit and an uncertain difference later do not prove that inflammation resolved or that the true effects differed between visits.

What are the limits?

Cell studies used small samples and often added calcitriol, the active vitamin D hormone, directly. Several shared investigators. They did not show that vitamin D3 supplements prevent harmful immune overactivation or reliably resolve inflammation in people. Research concentrations are not personal doses.

Read the full article below ↓

Vitamin D can change the size and timing of immune responses. In one laboratory study, measured expansion was greater than in similar cultures not given active hormone at day four, but relevant division measures were lower than the comparison at day seven. Other experiments found changes in restraining functions. The studies did not establish that supplements prevent harmful overactivation or resolve inflammation in people. The detailed counterpart is Vitamin D and the Timing of Immune Activation and Restraint: Full Evidence Review.

What was studied?

The review examined human cells in the laboratory. T cells help direct immune responses; they were tested after receiving signals to respond. Other experiments measured proteins that can reduce activation of other cells, and cells from inflamed rheumatoid joints. A separate blood-cell study tested whether different immune-cell types responded in the same direction. Human blood-marker results provided a limited comparison with supplementation. These experiments and trial analyses measured different outcomes. [1] [5] [2] [3] [4] [6]

The researchers often added calcitriol, the active hormone, directly to cells. This differs from taking vitamin D3 by mouth. The laboratory concentrations cannot be converted into supplement instructions. Some studies shared investigators; multiple assays do not become independent confirmations.

Did inflammatory signals fall?

In the Chauss experiments, a vitamin-D-dependent programme changed the signals released by activated helper T cells. They produced less interferon-gamma, an inflammatory signal, and more interleukin-10, which can help restrain responses. Interleukin-6 also increased and contributed in that setting. The cells did not simply become a usual type of cell that restrains immune responses. [1]

This is why Vitamin D and Cytokine Balance cannot be reduced to calling each signal good or bad in every situation. A change in one programme does not mean every immune activity fell. The study’s COVID-19 datasets were observational and did not test vitamin D treatment.

Why did timing matter?

Vera and colleagues compared active-hormone-exposed cells with similar comparison cells not given active hormone. Measured division and expansion were greater with hormone at day four, whereas relevant measures were lower than the comparison at day seven. These comparisons at each time do not prove a rise and fall in a person’s cell population. A single time point could therefore give an incomplete answer. Tests involving glutamine, a nutrient cells can use, supported a metabolic contribution. They did not prove a complete mechanism or clinical protection. Samples were small and the analysis of possible mechanisms was preliminary. [5]

Cell expansion, inflammatory signals and tissue recovery are different outcomes. A change in a cell culture does not establish that inflammation resolved in a person.

Could vitamin D preserve a restraining function?

Jeffery’s 2015 experiments tested CTLA-4, a protein that can reduce signals activating other T cells. Calcitriol preserved some measured regulatory functions during inflammatory stimulation. The study tested effects on activating signals and other cells, rather than relying only on a marker. The full checkpoint study is explained in Vitamin D, CTLA-4 and Immune Restraint: Full Study. It did not establish permanent tolerance or disease prevention. [2]

Some cells from inflamed rheumatoid joints were less sensitive to calcitriol than blood-derived cells. The pattern depended on the signal and cell state. It did not show that all memory cells were resistant or establish whether oral supplementation treated rheumatoid arthritis. [3]

Kundu’s study also found increased responses in one kind of blood immune cell and reduced responses in another. This limits any universal claim of immune suppression. Its small uncontrolled human component did not establish a clinical benefit. [4]

What remains uncertain?

The VITAL blood-marker reports came from one parent trial. The later report found lower high-sensitivity C-reactive protein, a blood inflammatory marker, at year two but did not establish a clear difference at year four. Other measured blood markers did not show a consistent reduction. This does not itself establish that the true effects differed between visits. Blood markers still do not directly establish tissue recovery. [6] [7]

Vitamin D and Systemic Regulation concerns whole-body regulation. From Cellular Cytokine Responses to Systemic Inflammation explains why cellular and systemic measurements should stay separate. Vitamin D and Immune Overactivation concerns harmful overactivation, but the studies here do not prove its prevention in people.

The effects depended on the cell, vitamin D form, existing inflammation and measurement time. These studies did not establish that supplements prevent harmful immune overactivation or resolve inflammation in people.

Primary sources

[1] Chauss D et al. Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. Nature immunology. 2022;23(1):62-74. DOI: 10.1038/s41590-021-01080-3. PMID: 34764490.

[2] Jeffery LE et al. Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function. PloS one. 2015;10(7):e0131539. DOI: 10.1371/journal.pone.0131539. PMID: 26134669.

[3] Jeffery LE et al. Decreased sensitivity to 1,25-dihydroxyvitamin D3 in T cells from the rheumatoid joint. Journal of autoimmunity. 2018;88:50-60. DOI: 10.1016/j.jaut.2017.10.001. PMID: 29066221.

[4] Kundu R et al. Cell-type-specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes. Immunology. 2017;150(1):55-63. DOI: 10.1111/imm.12669. PMID: 27608289.

[5] Vera AA et al. Vitamin D supports activated CD4+ T-cell proliferation through enhanced glutaminolysis. Frontiers in immunology. 2026;17:1791098. DOI: 10.3389/fimmu.2026.1791098. PMID: 42367775.

[6] Dong Y et al. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465.

[7] Costenbader KH et al. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704.

Related reading

Original sources

Source

Decreased sensitivity to 1,25-dihydroxyvitamin D3 in T cells from the rheumatoid joint

1,25(OH)2D3 had significantly less suppressive effect on Th17 cells (IL-17+IFNγ-) and Th17.1 cells (IL-17+IFNγ+) from SF compared to those from blood, and had no effect on SF CD4+ or CD8+ IFNγ+ T cell frequencies.

Publication details

[3] Jeffery LE et al. Decreased sensitivity to 1,25-dihydroxyvitamin D3 in T cells from the rheumatoid joint. Journal of autoimmunity. 2018;88:50-60. DOI: 10.1016/j.jaut.2017.10.001. PMID: 29066221.

Read more →